Alcon, Novartis' former eye disease unit, continues dealmaking spree with $770M Aerie acquisition - Endpoints News

After picking up two drugs from a Bob Langer spinout in a deal earlier this year, Alcon is staying busy. The former Novartis subsidiary focused on eye diseases is acquiring Aerie Pharmaceuticals in a $770 million buyout, the companies announced late Monday. T…

In drug development, the running joke is that you can conduct well-controlled experiments, with a placebo arm and a study drug cohort. “You can’t do that in finance,” as Karuna Therapeutics CFO Troy… [+721 chars]

full article...